Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US

被引：0
|
作者：
Aly, Abdalla
Bapat, Bela
Ray, Saurabh
Chen, Zhiyong
Botteman, Marc
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3386
引用
收藏
页数：3
相关论文
共 50 条
  • [31] RESULTS OF A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY OF LENALIDOMIDE IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
    O'Brien, Maureen
    Alonzo, Todd
    Cooper, Todd
    Levine, John
    Brown, Patrick
    Slone, Tamra
    Benettaib, Bouchra
    Biserna, Noha
    Poon, Jennifer
    Quan, Jackie
    Simcock, Mathew
    Weiss, Daniel
    Zimmerman, Linda
    Kolb, Edward
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [32] A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)
    Davids, Matthew S.
    Valero, Yesid Alvarado
    Diefenbach, Catherine
    Egan, Daniel N.
    Dinner, Shira N.
    Al Malki, Monzr M.
    Begna, Kebede
    Kallam, Avyakta
    Abedin, Sameem
    Cook, Rachel
    Javidi-Sharifi, Nathalie
    Dominguez, Edward
    Miao, Lu
    Ghalie, Richard G.
    Danilov, Alexey
    BLOOD, 2023, 142
  • [33] Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.
    Stein, Eytan M.
    Dinardo, Courtney Denton
    Pollyea, Daniel Aaron
    Fathi, Amir Tahmasb
    Roboz, Gail J.
    Altman, Jessica K.
    Stone, Richard M.
    Flinn, Ian
    Kantarjian, Hagop M.
    Collins, Robert
    Patel, Manish R.
    Stein, Anthony Selwyn
    Sekeres, Mikkael A.
    Swords, Ronan T.
    Medeiros, Bruno C.
    Knight, Robert D.
    Agresta, Samuel V.
    De Botton, Stephane
    Tallman, Martin S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.
    Pollyea, Daniel Aaron
    Dinardo, Courtney Denton
    de Botton, Stephane
    Stein, Eytan
    Roboz, Gail J.
    Mims, Alice S.
    Swords, Ronan T.
    Altman, Jessica K.
    Collins, Robert
    Mannis, Gabriel N.
    Uy, Geoffrey L.
    Donnellan, William Bruce
    Pigneux, Arnaud
    Fathi, Amir Tahmasb
    Liu, Hua
    Wu, Bin
    Attar, Eyal C.
    Tallman, Martin S.
    Stone, Richard M.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Gilteritinib-Based Combinations Improve Survival and Enhances Allogenic Transplant Eligibility in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Canadian Single Center Experience
    Kurup, Akhil Rajendra
    Gupta, Vikas
    Yee, Karen
    Maze, Dawn C.
    Minden, Mark D.
    Schuh, Andre
    Schimmer, Aaron D.
    Bankar, Aniket
    Chan, Steven M.
    Davidson, Marta Beata
    Richard-Carpentier, Guillaume
    Sibai, Hassan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S325 - S325
  • [36] Venetoclax (VEN) Plus Intensive Chemotherapy (IC) with FLAG-IDA in Patients (Pts) with Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Abaza, Yasmin
    Khan, Talha
    Dinner, Shira
    Frankfurt, Olga
    Altman, Jessica K.
    BLOOD, 2022, 140 : 9036 - 9037
  • [37] A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
    Daver, Naval G.
    Zhang, Weiguo
    Graydon, Richard
    Dawra, Vikas K.
    Xie, Jingdong
    Kumar, Prasanna
    Andreeff, Michael
    BLOOD, 2019, 134
  • [38] Treatment for Relapsed/Refractory Acute Myeloid Leukemia
    Thol, Felicitas
    Heuser, Michael
    HEMASPHERE, 2021, 5 (06): : E572
  • [39] Treatment of Relapsed/Refractory Acute Myeloid Leukemia
    Bose, Prithviraj
    Vachhani, Pankit
    Cortes, Jorge E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (03)
  • [40] Treatment of Relapsed/Refractory Acute Myeloid Leukemia
    Prithviraj Bose
    Pankit Vachhani
    Jorge E. Cortes
    Current Treatment Options in Oncology, 2017, 18
12345